Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 2
2012 2
2014 4
2015 2
2016 6
2017 2
2018 3
2019 6
2020 3
2021 3
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C, Hartig L, Weinelt N, Moser LM, Salzmann-Manrique E, Merker M, Wels WS, Tonn T, Bader P, Klusmann JH, van Wijk SJL, Rettinger E. Heim C, et al. Among authors: rettinger e. Mol Ther Oncol. 2024 Apr 11;32(2):200802. doi: 10.1016/j.omton.2024.200802. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38706988 Free PMC article.
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy.
Sharma A, Ren X, Rosato A, Sangiolo D, Wang Z, Tettamanti S, Zhang Y, Rettinger E, Fenix KA, Sommaggio R, Cappuzzello E, Schmidt-Wolf IGH. Sharma A, et al. Among authors: rettinger e. Cancer Immunol Immunother. 2024 Jan 27;73(2):21. doi: 10.1007/s00262-023-03605-1. Cancer Immunol Immunother. 2024. PMID: 38279995 Free PMC article.
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, Gradhand E, Ullrich E, Meister MT, Koerkamp MG, Holstege FCP, Drost J, Klusmann JH, Bader P, Merker M, Rettinger E. Heim C, et al. Among authors: rettinger e. Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.
Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors.
Jarisch A, Salzmann-Manrique E, Soerensen J, Sach G, Rettinger E, Willasch A, Bakhtiar S, Klarmann D, Bräuninger S, Moser L, Fekadu J, Hutter M, Klingebiel T, Klusmann JH, Bader P, Bonig H. Jarisch A, et al. Among authors: rettinger e. Br J Haematol. 2023 Jun;201(6):1159-1168. doi: 10.1111/bjh.18761. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36949601
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, Koenecke C, Bakhtiar S, Künkele A, Meisel R, Müller F, Müller I, Penack O, Rettinger E, Sauer MG, Schlegel PG, Soerensen J, von Stackelberg A, Strahm B, Hauer J, Feuchtinger T, Jarisch A. Bader P, et al. Among authors: rettinger e. Blood Adv. 2023 Jun 13;7(11):2436-2448. doi: 10.1182/bloodadvances.2022008981. Blood Adv. 2023. PMID: 36607834 Free PMC article.
Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A, Wiercinska E, Huenecke S, Bremm M, Cappel C, Hauler J, Rettinger E, Soerensen J, Hellstern H, Klusmann JH, Ciesek S, Bonig H, Bader P. Jarisch A, et al. Among authors: rettinger e. Transplant Cell Ther. 2022 Jul;28(7):366.e1-366.e7. doi: 10.1016/j.jtct.2022.04.017. Epub 2022 Apr 26. Transplant Cell Ther. 2022. PMID: 35472554 Free PMC article.
Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel.
Peinelt A, Bremm M, Kreyenberg H, Cappel C, Banisharif-Dehkordi J, Erben S, Rettinger E, Jarisch A, Meisel R, Schlegel PG, Beck O, Bug G, Klusmann JH, Klingebiel T, Huenecke S, Bader P. Peinelt A, et al. Among authors: rettinger e. Front Immunol. 2022 Mar 2;13:830773. doi: 10.3389/fimmu.2022.830773. eCollection 2022. Front Immunol. 2022. PMID: 35309367 Free PMC article.
39 results